Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Ihor, Bekersky"'
Publikováno v:
The Journal of Clinical Pharmacology. 56:365-374
A metabolic mechanism-based characterization of antiepileptic drug-drug interactions (DDIs) with clobazam in patients with Lennox-Gastaut syndrome (LGS) was performed using a population pharmacokinetic (PPK) approach. To characterize potential DDIs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea099ce8ee9245b6f308da90ff525819
https://doi.org/10.1002/jcph.603
https://doi.org/10.1002/jcph.603
Publikováno v:
The Journal of Clinical Pharmacology. 56:213-222
An integrative population pharmacokinetics (PPK)-based approach was used to characterize the effect of hepatic impairment on clobazam PK and its major metabolite in systemic circulation, N-desmethylclobazam (N-CLB). At therapeutic clobazam dosages, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab8e61b0918b0d6f25df400404446f83
https://doi.org/10.1002/jcph.586
https://doi.org/10.1002/jcph.586
Publikováno v:
Clinical therapeutics. 39(10)
Purpose A thorough QT study was conducted to assess the proarrhythmic potential of clobazam and its active metabolite, N-desmethylclobazam (N-CLB). Methods In this Phase I, single-site, randomized, double-blind, double-dummy, parallel-group study, he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5a2c30d9b8d798e6bbf2f11890aa214
https://pubmed.ncbi.nlm.nih.gov/28958437
https://pubmed.ncbi.nlm.nih.gov/28958437
Autor:
Paul Jarosinski, William W. Hope, Ihor Bekersky, Donald N. Buell, Nita L. Seibel, Thomas J. Walsh, Corina E. Gonzalez, Aziza T. Shad, Andreas H. Groll, Lauren V. Wood
Publikováno v:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
The safety, tolerability, and pharmacokinetics of the liposomal formulation of amphotericin B (L-AMB) were evaluated in 40 immunocompromised children and adolescents. The protocol was an open-label, sequential-dose-escalation, multidose pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19db5b01a5a1db5511aad6c30e96a424
Publikováno v:
Epilepsy & Behavior. 37:11-15
To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6072fc15c6a28b598d8195290515450
https://doi.org/10.1016/j.yebeh.2014.05.016
https://doi.org/10.1016/j.yebeh.2014.05.016
Tacrolimus (FK506) is a calcineurin inhibitor with potent immunomodulating properties. It has been marketed worldwide since 1993-1994 for the rejection of liver and kidney transplants (Prograf). The pharmacologic properties of tacrolimus resulted in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d3c91062dc339aa0dc4a308a7aed4e
https://doi.org/10.1053/sder.2001.29067
https://doi.org/10.1053/sder.2001.29067
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:340-353
Study objective To investigate potential drug-drug interactions between clobazam and cytochrome P450 (CYP) isoenzyme substrates, inhibitors, and inducers. Design Two, prospective, open-label, single-center, drug-drug interaction (DDI) studies and a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d8dcb9ed181f0187fff580447117e4
https://doi.org/10.1002/j.1875-9114.2012.01028.x
https://doi.org/10.1002/j.1875-9114.2012.01028.x
Autor:
Ihor Bekersky, Stephen D. Collins, Dwain Tolbert, Reid Patterson, Bernard S Jortner, Stephen Wanaski, Stephen M. Sagar, Mark Walzer, Robert H. Garman
Publikováno v:
NeuroToxicology. 32:963-974
Two toxicologic studies of vigabatrin were conducted with immature Sprague Dawley rats to characterize intramyelinic edema (IME) formation and assess potential impact on behavioral measures. Study 1 was a dosage-ranging characterization of overall to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78df7b8864094a2ddfd8d11437038eb7
https://doi.org/10.1016/j.neuro.2011.03.014
https://doi.org/10.1016/j.neuro.2011.03.014
Publikováno v:
Journal of clinical pharmacology. 56(2)
An integrative population pharmacokinetics (PPK)-based approach was used to characterize the effect of hepatic impairment on clobazam PK and its major metabolite in systemic circulation, N-desmethylclobazam (N-CLB). At therapeutic clobazam dosages, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::031af8194977cac652ad5bda0744f55b
https://pubmed.ncbi.nlm.nih.gov/26139309
https://pubmed.ncbi.nlm.nih.gov/26139309
Autor:
Rebecca Drummond, Victor Biton, David L. Wesche, James C. Cloyd, Ihor Bekersky, Dwain Tolbert, Mark Walzer, Deborah Lee
Publikováno v:
Epilepsia
Summary Objective To evaluate the safety, tolerability, and comparative pharmacokinetics (PK) of intravenous and oral carbamazepine. Methods In this phase 1, open-label study, adult patients with epilepsy on a stable oral carbamazepine dosage (400–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7ff20bc59106fb7602f90c9a2a975a
https://pubmed.ncbi.nlm.nih.gov/25982590
https://pubmed.ncbi.nlm.nih.gov/25982590